News | Contrast Media | May 03, 2021

The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet


Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, joints, rectally, body cavity or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, gadolinium-based contrast agents are preferred in MRI (magnetic resonance imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney.

View the MRI Contrast Agents comparison chart here.

According to analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.

The Contrast Agents/Media Global Market is Segmented

Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.

The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound.X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis and others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.

The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.

Based on end-user, contrast agents market is segmented into hospitals, diagnostic and ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics and gynecology (hysterosalpingography).

Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.

For more information: https://www.researchandmarkets.com/reports/5304974

View the MRI Contrast Agents comparison chart here.


Related Content

News | PET Imaging

April 24, 2024 — A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare ...

Time April 24, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group—lead by authors at the University of Toronto—have developed an approach for ...

Time April 23, 2024
arrow
News | FDA

April 23, 2024 — Royal Philips , a global leader in health technology, today announced its Philips Zenition 30 mobile C ...

Time April 23, 2024
arrow
News | Ultrasound Imaging

April 22, 2024 — GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which ...

Time April 22, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | ACR

April 15, 2023 — The American College of Radiology (ACR) released an update to its ACR Appropriateness Criteria (ACR AC) ...

Time April 13, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
Subscribe Now